IL1B and psoriasis: The nanoformulations of CUR were majorly able to decrease psoriasis inflammatory symptoms, PASI, TNF-α, IL-17, IL-22 and IL-1β levels, C-C chemokine receptor type 6 (CCR6) expression, the proliferation of psoriatic cells and occurrence of psoriatic lesions.